The systemic management of central nervous system metastases and leptomeningeal disease from advanced lung, melanoma, and breast cancer with molecular drivers: An Australian perspective.
Humans
Female
Carcinoma, Non-Small-Cell Lung
/ pathology
Breast Neoplasms
/ drug therapy
Lung Neoplasms
/ drug therapy
Australia
Central Nervous System Neoplasms
/ drug therapy
Melanoma
/ drug therapy
Meningeal Neoplasms
/ genetics
Neoplasms, Second Primary
Lung
/ pathology
Central Nervous System
/ pathology
CNS
breast
leptomeningeal
lung
melanoma
Journal
Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
01
08
2021
accepted:
14
01
2022
pubmed:
4
3
2022
medline:
22
11
2022
entrez:
3
3
2022
Statut:
ppublish
Résumé
The advent of systemic therapies with high intracranial efficacy in recent years is changing the therapeutic paradigm and renewing interest in the management of central nervous system (CNS) and leptomeningeal metastases from solid organ tumors. CNS metastases have traditionally heralded a dismal prognosis with median survival of 3-10 months, and were primarily treated with local therapeutic modalities, such as surgery or radiation therapy. Although these modalities still have a role in the management of CNS disease, newer agents, such as small molecule tyrosine kinase inhibitors and immune-checkpoint inhibitors, are now paving the way as an alternative therapeutic option for those with oligometastatic or low-volume intracranial disease, potentially eliminating or delaying the need for local treatment modalities in this setting. Herein, we summarize the systemic treatments with proven intracranial efficacy, currently approved for use in Australia for advanced mutation-driven non-small cell lung cancer, melanoma, and breast cancer, as well as novel agents in preclinical and clinical trial development.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
515-525Informations de copyright
© 2022 John Wiley & Sons Australia, Ltd.
Références
Rick J, Shahin M, Chandra A, et al. Systemic therapy for brain metastases. Crit Rev Oncol Hematol. 2019;142:44-50.
Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14:48-54.
Wang N, Bertalan M, Brastianos P. Leptomeningeal metastasis from systemic cancer: review and update on management. Cancer. 2018;124(1):21-35.
Brastianos P, Davies M, Margolin K, et al. Modern management of central nervous system metastases in the era of targeted therapy and immune oncology. Am Soc Clin Oncol Educ Book. 2019;39:e59-e69.
Chamberlain M, Baik C, Gadi V, et al. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol. 2017;19(1):i1-i24.
Clarke JL, Pao W, Wu N, et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010;99(2);283-286.
Ramalingam S, Vanseteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41-50.
Wu Y-L, Ahn M-J, Garassino M, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomised phase III trial (AURA3). J Clin Oncol. 2018;36(26):2702-2709.
Wakuda K, Yamaguchi H, Kenmotsu H, et al. A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer harbouring EGFR mutations: the OCEAN study (LOGIK 1603/WJOG 9116L). J Clin Oncol. 2020;38(15):9597.
Lin N, Lee E, Aoyama H, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015;16:e279-8.
Park S, Lee MH, Seong M, et al. A phase II, multicentre, two cohort study of 160mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol. 2020;31(10):1397-1404.
Soon YY, Leong C, Koh W, Tham I. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis. Radiother Oncol. 2015;114(2):167-172.
Peters S, Camidge R, Shaw A, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829-838.
Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390(10089):29-39. https://doi.org/10.1016/S0140-6736(17)30565-2.
Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet. 2019;7(5):437-446.
Camidge R, Kim H, Ahn MJ, et al. Brigatinib versus crizotinib in advanced ALK inhibitor-naïve ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. J Clin Oncol. 2020;38(31):3592-3603.
Bauer T, Shaw A, Johnson M, et al. Brain penetration of lorlatinib: cumulative incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer. Target Oncol. 2020;15(1):55-65.
Solomon B, Bauer TM, De Marinis F, et al. LBA2 lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): results of the phase II CROWN study. Ann Oncol. 2020;21(4):1180-1181.
Chuang C-H, Chen H-L, Chang H-M, et al. Systemic review and network meta-analysis of anaplastic lymphoma kinase (ALK) inhibitors for treatment-naïve ALK-positive lung cancer. Cancers. 2021;13:1966.
Shaw A, Felip E, Bauer T, et al. Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicentre, open-label phase 1 trial. Lancet Oncol. 2017;18(12):1590-1599.
Fischer H, Ullah M, de la Cruz C, et al. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro-Oncology. 2020;22(6):819-829.
Doebele R, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumors: integrated analysis of three phase 1-2 trials. Lancet. 2019;21(2):271-282.
Shaw A, Solomon B, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet. 2019;20(12):1691-1701.
Kirkwood J, Long G, Trefzer U, et al. BREAK-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/K mutation-positive melanoma with brain metastases (mets). J Clin Oncol. 2012;30(15):8501-8501.
Davies M, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet. 2017;18(7):863-873.
Holbrook K, Lutzky J, Davies M, et al. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: a case series. Cancer. 2020;126(3):523-530.
Phase II Study of Cobimetinib in Combination with Vemurafenib in Active Melanoma Brain Metastases (coBRIM-B) [last updated Oct 12, 2017]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2014. Available from: clinicaltrials.gov/ct2/show/NCT02230306.
Heinzerling L, Eigentler T, Fluck M, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019;4(3):e000491.
Tawbi H, Forsyth P, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379:722-730.
Long G, Atkinson VG, Lo S, et al. Long-term outcomes from the randomised phase II study of nivolumab (nivo) or nivolumab+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): anti-PD1 brain collaboration (ABC). Ann Oncol. 2019;30(5):V534.
Hong A, Fogarty G, Dolven-Jacobsen K, et al. Adjuvant whole-brain radiation therapy compared with observation after local treatment of melanoma brain metastases: a multicenter, randomised phase III trial. J Clin Oncol. 2019;37(33):3132-3141.
Chan WL, Lam TC, Lam KO, et al. Local and systemic treatment for Her2-positive breast cancer with brain metastases: a comprehensive review. Ther Adv Med Oncol. 2020;12. https://doi.org/10.1177/1758835920953729.
Fares J, Kanojia D, Rashidi A, et al. Landscape of combination therapy trials in breast cancer brain metastasis. Int J Cancer. 2020;147(7):1939-1952.
Swain SM, Baelga J, Miles D, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25(6):1116-1121.
Lin N, Pegram M, Sahebjam S, et al. Pertuzumab plus high-dose trastuzumab in patients with progressive brain metastases and Her2-positive metastatic breast cancer: primary analysis of a phase II study. J Clin Oncol. 2021;39(24):2667-2675. https://doi.org/10.1200/JCO.20.02822.
Montemurro F, Delaloge S, Barrios CH, et al. Trastuzumab emtansine (T-DM1) in patients with Her2-positive metastatic brain cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol. 2020;31(10):1350-1358. https://doi.org/10.1016/j.annonc.2020.06.020.
Cortes J, Kim S, Chung W, et al. LBA1 - trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with Her2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study. Ann Oncol. 2021;32(5):S1283-S1346.
Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from Her2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):63-71.
Kurihara H, Hamada A, Yoshida M, et al. 64Cu-DOTA-trastuzumab PET imaging and Her2 specificity of brain metastases in Her2-positive breast cancer patients. EJNMMI Res. 2015;5:8.
He M, Wei M. Reversing multidrug resistance by tyrosine kinase inhibitors. Chin J Cancer. 2012;31(3):126-133.
Minari R, Bordi P, Tiseo M. Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance. Transl Lung Cancer Res. 2016;5(6):695-708. 10.21037/tlcr.2016.12.02.
Patel M, Eckburg A, Cantiwala S, et al. Resistance to molecularly targeted therapies in melanoma. Cancers. 2021;13(5):1115.
Pietila M, Sahgal P, Peuhu E, et al. SORLA regulates endosomal trafficking and oncogenic fitness of Her2. Nat Commun. 2019;10:2340.
Morgan AJ, Giannoudis A, Palmieri C. The genomic landscape of breast cancer brain metastases: a systematic review. Lancet. 2021;22(1):e7-e17. https://doi.org/10.1016/S1470-2045(20)30556-8.
A Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants with Advanced Non-Small Cell Lung Cancer (CHRYSALIS) [last updated May 18, 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2015. Available from: clinicaltrials.gov/ct2/show/NCT02609776.
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) [last updated Feb 5, 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2020. Available from: clinicaltrials.gov/ct2/show/NCT04487080.
A Study of Repotrectinib (TPX-0005) in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) [last updated Feb 1, 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2017. Available from: clinicaltrials.gov/ct2/show/NCT03093116.
Skoulidis F, Li B, Dy G, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371-2381.
Mathieu L, Larkins E, AKinboro O, et al. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations. Clin Cancer Res. 2022;28(2):249-254. https://doi.org/10.1158/1078-0432.
Wolf J, Seto T, Han J-Y, et al. Capmatinib in MET exon14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383:944-957.
Paik P, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383:931-943.
Nivolumab with Trametinib and Dabrafenib in Treating Patients with BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma (TRIDeNT) [last updated April 5, 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2016. Available from: clinicaltrials.gov/ct2/show/NCT02910700.
A Study of Tucatinib vs. Placebo in Combination with Capecitabine & Trastuzumab in Patients with Advanced Her2+ Breast Cancer (HER2CLIMB) [last updated Sept 28, 2020]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2015. Available from: clinicaltrials.gov/ct2/show/NCT02614794.
A Study of Osimertinib with or without Chemotherapy as 1st Line Treatment in Patients with Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) [last updated March 1, 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2019. Available from: clinicaltrials.gov/ct2/show/NCT04035485.
A Randomised Phase II Trial of Osimertinib with or without SRS for EGFR Mutated NSCLC with Brain Metastases (OUTRUN) [last updated Mar 9, 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2018. Available from: clinicaltrials.gov/ct2/show/NCT03497767.
Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-Small Cell Lung Cancer with EGFR or HER2 Mutation (WU-KONG1) [last updated April 9, 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2019. Available from: clinicaltrials.gov/ct2/show/NCT03974022.
A Study of the Anti-PD1 Antibody PDR001, in Combination with Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i) [last updated April 14, 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2016. Available from: clinicaltrials.gov/ct2/show/NCT02967692.
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients with Metastatic or Unresectable Locally Advanced Melanoma (TRILOGY) [last updated Nov 19, 2020]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2016. Available from: clinicaltrials.gov/ct2/show/NCT02908672.
Anti-PD1 Brain Collaboration and Radiotherapy Extension (ABC-X Study) (ABC-X) [last updated Jun 9, 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2017. Available from: clinicaltrials.gov/ct2/show/NCT03340129.
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-Small Cell Lung Cancer [last updated Aug 3, 2020]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2016. Available from: clinicaltrials.gov/ct2/show/NCT02681549.
Bevacizumab and Atezolizumab with or without Cobimetinib in Treating Patients with Untreated Melanoma Brain Metastases [last updated Jun 11, 2020]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2017. Available from: clinicaltrials.gov/ct2/show/NCT03175432.
An Open-Label, Randomised, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-Dose and High-Dose Regimen in Patients with BRAFV600-Mutant Melanoma Brain Metastasis (POLARIS) [last updated May 6, 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2019. Available from: clinicaltrials.gov/ct2/show/NCT03911869.
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-Type Melanoma with Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-Positive Melanoma with Central Nervous System Metastases [last updated May 18, 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2018. Available from: clinicaltrials.gov/ct2/show/NCT03625141.
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases [last updated May 13, 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2020. Available from: clinicaltrials.gov/ct2/show/NCT04511013.
Stereotactic Radiosurgery Added to Binimetinib and Encorafenib in Patients with BRAFV600 Melanoma with Brain Metastasis (BECOME-MB) [last updated Feb 23, 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2020. Available from: clinicaltrials.gov/ct2/show/NCT04074096.
HKI-272 for Her2-Positive Breast Cancer and Brain Metastases [last updated May 21, 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2011. Available from: clinicaltrials.gov/ct2/show/NCT01494662.
Basket Study of Neratinib in Participants with Solid Tumors Harboring Somatic Her2 or EGFR Exon 18 Mutations (SUMMIT) [last updated May 19, 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine; 2013. Available from: clinicaltrials.gov/ct2/show/NCT01953926.